- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01540526
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
Pharmacodynamic Study Using FLT-PET/CT in Patients With Prostate and Other Solid Malignancies Treated With an Interrupted High-dose Axitinib Schedule
The main purpose of this study is to learn more about the safety of an investigational drug, axitinib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. Researchers will also see what changes happen to the tumors while taking the axitinib and after it is stopped (during the scheduled breaks), and what changes in the tumor may be responsible for this growth. This will be done by using a special kind of scan called an 18F-FLT PET/CT. This scan is considered an investigational type of scan and is not used for clinical care. These scans are not approved by the FDA, their use in this study is just for research purposes.
In addition, the investigators want to find out how the drug is processed and distributed in the human body. The investigators will also look at how different types of cancer are affected by axitinib.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Carbone Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed solid malignancy (excluding lymphoma) that is metastatic or unresectable and for which no standard therapy exists.
- Patients must have measurable disease
- Must be >/= 18 years of age
- All patients need to be willing to undergo planned pharmacodynamic assessments, including serial PET imaging, plasma markers, and pharmacokinetic sampling.
Exclusion Criteria:
- Patients who have had chemotherapy, radiotherapy, experimental therapy or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered (to grade -Patients may not be receiving any other investigational agents.
- Patients with prior anti-VEGF directed therapy may be allowed only if approved by the PI and greater than 8 weeks since last exposure
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to axitinib
- Patients with poorly controlled hypertension
- Patients who require use of therapeutic doses of coumarin-derivative anticoagulants
- Patients with any condition that impairs their ability to swallow and retain axitinib tablets are excluded.
- Patients with any of the following conditions are excluded: Serious or nonhealing wound, ulcer, or bone fracture; History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment; Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry; History of myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry; History of pulmonary embolism within the past 12 months; Class III or IV heart failure as defined by the NYHA functional classification system.
- Patients without appropriate lesion on CT scan for FLT-PET/CT imaging
- CYP3A4 inducers/inhibitors medications will be reviewed by the Principal Investigator.
- Steroid use is not recommended during axitinib treatment
- Patients with a pre-existing thyroid abnormality who are unable to maintain thyroid function in the normal range with medication are ineligible.
- Patients with known brain metastases should be excluded
- HIV-positive patients on combination antiretroviral therapy are ineligible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Safety cohort
6 evaluable patients with RECIST measurable solid malignancies will be enrolled to establish the safety and toxicity of axitinib at 7 mg PO BID days 1-14 in 21 day cycles.
|
7 mg PO BID days 1-14 in 21 day cycles.
|
Experimental: Pharmacodynamic cohort
PD cohort A: Up to 6 patients with metastatic castrate-resistant prostate cancer (evidence of soft-tissue metastases amendable to FLT-PET/CT imaging), and PD cohort B: Up to 12 patients with other solid malignancies (evidence of radiographic metastases amendable to FLT-PET/CT imaging) will be enrolled with scans obtained at baseline, peak exposure, and peak withdrawal of axitinib, in cycle#1, with repeat imaging in select patients in PD cohorts A and B at a later cycle of therapy.
|
7 mg PO BID days 1-14 in 21 day cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacodynamic change on FLT-PET/CT
Time Frame: baseline, cycle 1 weeks 2 and 3, pre-cycle 3, cycle 3 weeks 2 and 3
|
baseline, cycle 1 weeks 2 and 3, pre-cycle 3, cycle 3 weeks 2 and 3
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Glenn Liu, M.D., University of Wisconsin, Madison
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CO10907
- A534260 (Other Identifier: UW Madison)
- SMPH\MEDICINE\HEM-ONC (Other Identifier: UW Madison)
- 2011-0575 (Other Identifier: Institutional Review Board)
- NCI-2012-00142 (Registry Identifier: NCI Trial ID)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Malignancies
-
National University Hospital, SingaporeRecruitingMetastatic Solid Malignancies | Advance Solid MalignanciesSingapore
-
AHS Cancer Control AlbertaCross Cancer InstituteWithdrawnMetastatic Solid Malignancies | Locally Advanced Solid MalignanciesCanada
-
Kiromic, Inc.TerminatedCancer | Progressive Solid Malignancies | Refractory Solid MalignanciesUnited States
-
AstraZenecaQuintiles, Inc.CompletedSolid MalignanciesUnited Kingdom
-
University Hospital, Clermont-FerrandAmgenTerminatedSolid Malignancies
-
AstraZenecaCompletedCancer | Solid Tumors | Advanced Solid MalignanciesJapan
-
AstraZenecaTerminatedCancer | Solid Tumors | Advanced Solid MalignanciesJapan
-
University Hospital, Clermont-FerrandAmgenUnknown
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
Clinical Trials on axitinib
-
PfizerCompletedNeoplasmsPoland, United States, Spain
-
Peking University Cancer Hospital & InstituteUnknownAdvanced Mucosal MelanomaChina
-
Acceleron Pharma Inc. (a wholly owned subsidiary...TerminatedAdvanced Renal Cell CarcinomaUnited States
-
PfizerCompletedLung Neoplasms | Carcinoma, Non-small Cell LungUnited States, Germany
-
PfizerCompletedCarcinoma, Renal CellUnited States, Spain, Japan, Germany, Czechia, Russian Federation
-
Chinese University of Hong KongCompleted
-
AkesoRecruitingRenal Cell Carcinoma | First-line TreatmentChina
-
Spanish Cooperative Group for the Treatment of...TerminatedColorectal CarcinomaSpain
-
Assistance Publique - Hôpitaux de ParisPfizerCompletedcT2a N0NxM0 Renal TumorFrance
-
Bart NeynsPfizerCompleted